EUVIMEDEUVIMED entdecken
Crossref

Clinical Efficacy and Tolerability of Sorafenib in Dogs With Advanced Carcinomas

Doyun Kim iD, Taekun Kim, Youngsun Kim, Hojin Jang, Hanbin Lee, Youngmin Yun, Mihyun Choi, Woo-Jin Song iD

Veterinary and Comparative Oncology · 2026

DOI: 10.1111/vco.70047 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Veterinary and Comparative Oncology, 2026. Verfasst von Doyun Kim und 7 weiteren Autor:innen. Beteiligte Einrichtung: BON Animal Medical Center, Suwon, Republic of Korea. Hauptthemen laut MEDLINE: Sorafenib, Dog Diseases, Antineoplastic Agents, Carcinoma. Die Arbeit nennt 35 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Advanced carcinomas in dogs present significant therapeutic challenges with limited treatment options and poor prognoses. Sorafenib, a multi‐kinase inhibitor targeting RAF and receptor tyrosine kinases, has demonstrated antitumor activity and tolerability in preclinical veterinary studies; however, clinical data remain limited. This prospective, open‐label cohort study evaluated the tolerability and clinical efficacy of oral sorafenib (6 mg/kg once daily) in 24 dogs with cytologically or histologically confirmed unresectable, recurrent, or metastatic carcinomas. Tumour response was assessed using RECIST criteria, and adverse events were graded according to VCOG‐CTCAE v2.0. Stable disease at 1 month was observed in 14 of 18 evaluable dogs (77.8%), yielding an overall clinical benefit rate of 58.3%. Median time to progression and overall survival were 51 days (95% CI, 14–115) and 65 days (95% CI, 49–143), respectively. Dogs presenting with lameness ( n = 7) showed significantly longer time to progression and overall survival than those without ( p < 0.01). Adverse events occurred in 9 of 24 dogs (37.5%), primarily mild lameness (29%) and gastrointestinal signs. Weight gain at 1 month, observed in 66.7% of dogs, was significantly associated with clinical benefit ( p = 0.005; OR = 45.0; 95% CI, 1.8–1127.7). Sorafenib was well tolerated and provided measurable clinical benefit in dogs with advanced carcinomas. Lameness may represent a prognostic biomarker, and weight gain may reflect a favourable clinical response. These findings support further investigation of sorafenib and other tyrosine kinase inhibitors in veterinary oncology.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

SorafenibDog DiseasesAntineoplastic AgentsCarcinomaNiacinamidePhenylurea CompoundsAnimalsDogsFemaleMaleTreatment OutcomeProspective Studies

Stichwörter der Autor:innen

carcinomaclinical benefitdogssorafenibtolerabilitytyrosine kinase inhibitor

Substanzen

SorafenibAntineoplastic AgentsNiacinamidePhenylurea Compounds

Autor:innen und Institutionen

  • BON Animal Medical Center, Suwon, Republic of Korea.
  • Laboratory of Veterinary Internal Medicine, College of Veterinary Medicine, Jeju National University, Jeju, Republic of Korea.
  • Signature Animal Medical Center, Seoul, Republic of Korea.

ORCID-Profile: Doyun Kim, Woo-Jin Song

Zitieren

APA

Kim, D., Kim, T., Kim, Y., Jang, H., Lee, H., Yun, Y., Choi, M., & Song, W. J. (2026). Clinical Efficacy and Tolerability of Sorafenib in Dogs With Advanced Carcinomas. Veterinary and Comparative Oncology. https://doi.org/10.1111/vco.70047

Vancouver

Kim D, Kim T, Kim Y, Jang H, Lee H, Yun Y, et al. Clinical Efficacy and Tolerability of Sorafenib in Dogs With Advanced Carcinomas. Veterinary and Comparative Oncology. 2026. doi:10.1111/vco.70047

BibTeX
@article{Kim2026,
  author = {Kim, Doyun and Kim, Taekun and Kim, Youngsun and Jang, Hojin and Lee, Hanbin and Yun, Youngmin and Choi, Mihyun and Song, Woo-Jin},
  title = {Clinical Efficacy and Tolerability of Sorafenib in Dogs With Advanced Carcinomas},
  journal = {Veterinary and Comparative Oncology},
  year = {2026},
  doi = {10.1111/vco.70047}
}
Kostenlos starten →